A four step process of high quality modelling of existing data, deconstruction, identification of replacement cores and an innovative synthetic re-growth strategy led to the rapid discovery of a novel oral series of PI3K inhibitors with promising selectivity and excellent in vivo characteristics.
Introduction
The phosphoinositide-3-kinases (PI3Ks) are a family of lipid kinases that are implicated in the development of a range of diseases, including respiratory inflammation. 1, 2 They comprise three classes based on structure, mode of regulation and phospholipid substrate. The class I targets have been extensively investigated due to their role in various cancers and inflammatory disease, 3 with their biochemical role mediating the phosphorylation of phosphatidylinositol (4,5)-diphosphate (PtdIns(4,5)P2), to produce phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3). 4 A number of studies have highlighted the correlation between PI3K-mediated PIP3 production and T cell cytokine release 5 , mast cell degranulation, 6 neutrophil chemotaxis, 7 and the production of reactive oxygen species. 8 These cell behaviours have been implicated in the development of respiratory inflammation and a range of cancers. Of the known isoforms, PI3K is found to be predominantly expressed in leucocytes suggesting it is a promising target for the treatment of asthma, 9 COPD, 10 and autoimmune disorders. 11 From a drug discovery perspective, selectivity among the isoforms is an important consideration; both PI3K and  knock-out mice are viable and display some impairments of immune cell functions, 12, 13 however, PI3K and β knock-outs have been shown to be embryonically lethal. 12 We recently reported the discovery of an inhaled clinical candidate GSK2292767 (1, Figure 1 ) as a potent and selective PI3K inhibitor with promising in vivo properties as a potential therapy for respiratory indications 14 . This compound is structurally related to GSK2269557, also an inhaled therapy and currently in Phase II trials for COPD and asthma. Orally bioavailable compounds such as IPI-145 15 and GS-1101 (CAL-101, Idelalisib) 16 have previously been reported and advanced through clinical studies for oncology indications. Compounds of a similar structural genus have also appeared more recently, for example UCB-5857 and TGR-1202. All derive from the same chemical series which generally possesses mixed PI3K/ inhibition and this lack of selectivity creates difficulties in delineating the role of either isoform in inflammatory disease. More recently still researchers from Amgen reported potent, selective and orally bioavailable PI3K inhibitors for the treatment of inflammatory disorders (e.g. AM-8508, 2) 17 and Novatis have progressed CDZ-173 into phase III trials for the treatment of activated PI3K delta syndrome. Taken together these events highlight the significant and continuing level of interest associated with this promising therapeutic target. In the current study, we disclose our early efforts towards the discovery of a series of PI3K selective, orally bioavailable compounds exemplified by the dihydroisobenzofuran derivative 3 ( Figure 1 ) derived from our existing inhaled asset 1 as a potential therapy for respiratory disorders. The aim of the study was to discover an alternative core with reduced clearance and increased bioavailability whilst retaining the potential to deliver the class-leading levels selectivity demonstrated by compounds such as 1. 
Results and Discussion
Our progenitor compound 1 was developed for delivery by the inhaled route and exhibited negligible oral bioavailability (< 2%) with very low exposure (Cmax <2ng/mL, 3mg/kg p.o.) and only a small sub-set of the compounds prepared in this series possessed moderate bioavailability and clearance.
With this in mind, we elected to pursue a four stage approach in order to evolve a series more suited to oral adsorption. 1) Utilise all available information to guide future approaches. 2) Deconstruct the current series to identify key features and provide an efficiency baseline. 3) Replace or remove perceived vulnerable moieties in the deconstructed molecules to provide a wide range of future options. 4) Select options with distinct risk profiles for re-growth/optimisation.
Step 1 -Utilisation of legacy information. Replacement of the indazole core was motivated in part by a desire to reduce the aromatic ring count 18 but primarily by contemporaneous literature reports that implicated the indazole group 19 as a target for time-dependent P450 inhibition. The general design strategy involved tuning of TPSA 20 (<135 Å   2 ) and limitation of molecular weight through consideration of ligand efficiency. 21 To further refine our approach two proprietary data-sets were inspected with a view to minimise oral dose. These were factors affecting clearance (in vitro and in vivo) and cellular potency/drop off. Whilst the clearance data presented no potentially transferable trends the data from the cell assays provided significantly more insight. The difference between the primary assay and cellular whole blood (bio phase) assay was calculated and this difference was modelled using a multivariate data analysis technique called Partial Least Squares regression, 22 involving a standard set of physicochemical descriptors. The model was used to identify and explore potential relationships between molecular properties and the measured difference. The Loadings Plot (Figure 2 ) explores the relationship between variables themselves and also between response in
question. An examination of the plot highlighted three clusters of variables which led to assessment of which parameters were important. The associated Coefficient Plot summarises the magnitude and direction of influence of each variable.
Three key trends emerged from the data: i) Variables 5-9 are calculations of lipophilicity and appeared to be associated with a detrimental effect on drop-off between enzyme and whole blood potency; ii) Variables 11 and 12 suggested that ionisation, in particular addition of a basic centre, was beneficial to minimizing the drop-off between enzyme and biofluid activity; iii) The group of variables 23, 24 and 25 related to increased hydrogen bond donor count were detrimental to whole cell activity. The impact of lipophilicity and basic centres was attributed primarily to modulation of protein binding for which optimisation was not a priority; however, the negative impact of hydrogen bond donors, but not acceptors, drew our attention and impacted on our subsequent design strategy (vide infra). It is interesting to note that PI3Kdelta potency (variable 2) positively correlates with cellular drop off, albeit with very high variability, and it is not unlikely that this observation results from a relationship between lipophilicity and potency. and Var 25 (estate.amideOtoNH-av). NB Var 2 is PI3K delta potency.
Step 2 -Deconstruction. A deconstruction (Dx, Figure 3 ) of compound 1 was performed to establish the minimum necessary pharmacophore and maximal potential efficiency of the lead series. It was anticipated that scanning for replacement components at a reduced complexity level would be considerably more synthetically tractable. Furthermore, scanning with fully-elaborated compounds runs the risk of small changes in optimal binding pose of the core preventing efficient binding of the entire molecule. For efficiency measurements we adopted Binding Efficiency Index 23 (BEI = 1000 x (pIC50/MW)) as our efficiency metric given that in our hands it proved to be intuitive to use yet correlates 24 very well with the more widely used Ligand Efficiency (LE). The deconstruction was conducted with some knowledge of the binding of the molecule 14 gleaned from homology modelling prior to the later generation of a crystal structure. The indazole core fragment (red) occupies the kinase 'hinge' region, the pyridyl sulfonamide (blue) entered the lipid-kinase 'back' pocket whilst the oxazole/morpholino group (magenta) occupied a vector that delivered majority of selectivity for PI3K. The parent pyridine sulfonamide back-pocket binder (blue) was chosen as a structural lock. BEI calculations suggested that truncate 4 should be significantly above the limit of detection of the assay (pIC50 ~ 5) assuming a BEI of 18-20, hence allowing replacement hinge binding groups to be profiled.
Synthesis and evaluation of 4 (Table 1) confirmed the anticipated level of potency against PI3K, validating its use as a benchmark for replacement groups.
Step 3 -Identification of replacement hinge-binding groups. A variety of potential hinge-binding groups were then scanned and one of the most promising hits from this exercise was the dihydroisobenzofuran analogue 5 (Table 1) as a potentially novel replacement. This moiety increased solubility which was perhaps surprising given the higher measured LogD of the compound. We reasoned that this may be the result of destabilisation of the solid form as a consequence of reduced planarity and elimination of inter-molecular hydrogen bonds. This observation, coupled with the previous analysis suggesting the benefit of reduced HBD count, encouraged us to re-institute the selectivity vector on this template to establish the potential for obtaining selectivity, whole blood efficacy and favourable DMPK parameters. Step 4 -Re-growth and optimisation. Having established the feasibility of replacing the indazole core, the subsequent phase of the optimisation trajectory focused on re-establishing the selectivity vector at the 6-position of the dihydroisobenzofuran template. The design hypothesis at this stage focused on generating compounds that would facilitate a thorough comparison with the indazole series and lead to an understanding of how well the SAR would transfer between the two series. To select the most appropriate functional groups for the 6-position, we considered the structures of PI3K compounds previously synthesised in our laboratories, focusing on the key pyridylsulfonamide motif. The subset of compounds identified from this approach was further filtered through applying physicochemical property constraints that would be likely to furnish compounds with oral bioavailability. This analysis led to the identification of six potential substituents for inclusion at the 6-position of the dihydroisobenzofuran which spanned a variety of different chemotypes and offered a range of PI3K
class I selectivity profiles. The substituents of interest are shown in Figure 4 as part of the dihydroisobenzofuran motif, with calculated physicochemical parameters shown in Table 2 . The calculated physicochemical data is summarised in Table 2 . In addition to reduced hydrogen bond donor count, target compounds had lower TPSA than the progenitor inhaled compound 1 and we anticipated that this could potentially translate into improved oral exposure. 20 Other aspects of the physicochemical profile such as number of aromatic rings are lower, leading to potential improvements in Property Forecast Index (PFI), again increasing the probability of enhancing oral exposure. 18 The overall hydrogen bond donor count is included in the table; however, it is worth noting that all of the compounds contain one fewer donor than the corresponding progenitor indazoles. 
Chemistry
Reduced complexity analogues 4 and 5 were prepared using a Suzuki-Miyaura coupling from the pinacol boronic ester 11, Scheme 1. trimerisation of terminal alkynes preferentially installs the required meta arrangement of R4 and R6.
Judicious selection of these groups allows excellent flexibility to the medicinal chemist and synthesis of a wide variety of targets in short order (4-6 steps). Literature reports 25 suggested that trimethylsilyl tethered diynes (R6=TMS) exhibit excellent regiochemistry in this reaction and ipso substitution of the resulting aryl silane to iodide is well known (vide infra). It is worth noting that the route also provides the opportunity to make other changes to the core framework. For example use of nitriles (A=N) allows access to pyridyl analogues and elaboration at R2 and R7 readily facilitates substitution adjacent to the hinge-binding oxygen atom, therefore the investment was made in enabling this potentially challenging chemistry.
Scheme 2 Synthetic plan for the utilisation of 2+2+2 trimerisation chemistry.
Alkyne 13 was prepared as indicated in Scheme 3 and the TMS-protected bispropargylether 12 prepared in one step from propargyl ether according to the literature procedure. The synthesis of the target compounds is described in Scheme 4. Optimisation of cyclotrimerisation conditions revealed that cyclopropylmethyl ether (CPME) was preferable to the commonly used dichoroethane as solvent. 27 The key aryl silane intermediate 14 was thus obtained in good yield with either a 1.2 eq excess of 12 or a 2.0 eq excess of 13. Ipso substitution of 14 with iodine monochloride then provided the iodo derivative 15 in excellent yield. Palladium-mediated cross coupling provided 6
and 7 using either a Negishi protocol 28 or modified Suzuki-Miyaura procedure, 29 The in vitro potencies of the target compounds were measured in a homogenous time-resolved fluorescence assay as described previously. 14 The results from these assays (Table 4) Based on this promising initial data, and to more fully benchmark this nascent lead series, a selection of compounds was made for further profiling in both whole blood 14 to assess the cellular activity of each compound and DMPK 30 assays, as well as other developability screening. The results of these studies are summarised in Table 5 . In vivo PK data in Table 5 were obtained in the CD Sprague male rat following administration of 1mg/kg oral and iv doses. *AUC0-t quoted.
Comparing the whole blood potencies for the newly synthesised compounds shows a drop off cellular activity of at least ten fold or greater for compounds 6 and 10. By contrast, compound 3 exhibits only minimal attenuation in cellular potency compared to the isolated enzyme data. A likely contributor to this difference is protein binding given that compound 3 has an estimated free fraction of 36%, whereas the other analogues examined have an estimated free fraction of 10% or less. It is worth noting that whilst these compounds are substantially weaker than the inhaled lead in whole blood cell assays; however, there is a stronger imperative for potency for an inhaled molecule due to the necessity of a very low dose. The whole blood activity of 3, 6 and 10 compare favourably with oral compounds in clinical development, for example the PI3K inhibitor IPI-145 inhibits basophil degranulaton with an IC50 of 96nM (pIC50~7.0) in whole blood 15 .
All three compounds display much improved metabolic stability when compared to the inhaled lead 1 in both in vitro and in vivo studies. In vitro clearance (IVC) levels in all species investigated are low to moderate, whilst rat in vivo clearance for compound 3 of less than 14 mL/min/Kg equates to less than 20% liver blood flow ( Table 5 ). The slightly elevated observed clearance of morpholine 3 with respect to oxadiazole 6 and pyridine 10 could be attributed to the lower level of protein binding (HSA), which may increase the fraction of drug exposed to organs of metabolism and excretion. The relatively low volumes of distribution for compounds 6 and 3 result in lower half-lives compared to pyridine analogue 10. It was reasoned that further optimisation of the 6-position (e.g. modulation of the basic amine) could increase volume of distribution and positively impact the half-life. Low bioavailability is observed for pyridine 10 despite its low systemic clearance and excellent in vitro passive permeability measured on MDCK cells. First pass metabolism or poor absorption from the GI tract are therefore unlikely causes of the low bioavailability and it is more likely that this is attributed to the low solubility of pyridine 10 (50 µg/mL) when compared to the other dihydroisobenzofuran analogues examined. Oxadiazole 6 and morpholine 3 show significantly higher bioavailability than the inhaled lead 1, thus validating the initial design hypothesis in controlling physicochemical properties. Furthermore, morpholine 3 is among a paucity of compounds from this chemotype which exhibit both oral bioavailability and greater than 20 fold PI3K class I selectivity in isolated enzyme assays. In addition to this, compound 3 also exhibited excellent selectivity against a varied panel of kinases and other enzymes. 31 Based on all of the above, we believe that the dihydroisobenzofuran series represents a significant advance in the design of selective PI3Kδ compounds which are suitable for oral administration.
Compound 3 was also successfully co-crystallised with PI3K which confirmed the proposed binding mode with the kinase (Figure 5) . From our earlier studies, the indazole was shown to be a hinge binding motif 14 and this interaction is effectively maintained by the dihydroisobenzofuran, albeit that any interaction between the indazole NH and the hinge has been lost. The 6-position substituent forms a similar vector to that observed with the inhaled lead 1; however, the core benzenoid ring appears to be rotationally displaced by approximately 15 degrees which suggests that the optimal 6 position groups could differ between the two series. It is also worth noting that the morpholine substituent does not reach the same region of the protein as that occupied by 1 leading to the hypothesis that further selectivity can be obtained. Given the rotational displacement of the core it is postulated that complete re-optimisation of the linking group is required to allow the morpholine group to access the region occupied by 1. Figure 5 . X-ray structure of compound 3 (cyan) co-crystallised with PI3K and over-layed with a crystal structure of compound 1 (orange).
Based on its promising oral bioavailability and encouraging level of cellular potency the morpholine analogue 3 was progressed to an in vivo pharmacodynamic assay to determine its efficacy in a disease relevant animal model. In our previous report a Brown Norway rat acute OVA model of lung inflammation was used 14 . Compound 3 was assessed using this model whereby OVA challenge is administered 30 minutes after oral delivery. Significant protection against eosinophil recruitment was achieved by compound 3 at 3 mg/kg p.o (Figure 6 ) whereas failure to achieve significance at 9mg/kg is primarily attributed to two poorly responding rats in this group.
The pharmacokinetic data from the study is presented in Table 6 along with the comparative data from the pilot pharmacokinetic study. Interestingly 3 achieved lower exposure in the OVA study at 3mg/kg when compared to the pilot study (1mg/kg) which may be result from strain dependency and/or differences in dose formulation. The blood concentration of 3 one hour after dosing, i.e. 30 minutes after OVA challenge, are 0.19uM and 1.27uM for the 3mg/kg and 9mg/kg groups respectively which compare very favourably with the pIC50 in human whole blood (6.6, 0.25uM, vide supra). The estimated free drug concentrations at this time-point are also provided.
From consideration of all the above data, morpholine 3 represents the inception of a promising series of PI3Kδ inhibitors with good oral bioavailability and robust levels of in vivo efficacy. This compares favourably to the benchmark set by the orally bioavailable dual PI3Kγ/δ dual inhibitor IPI-145, which demonstrates similar levels of in vivo efficacy in a related pharmacodynamic study and has recently completed a Phase 2a trial for asthma.
This highly encouraging data provides additional validation for the design strategy adopted in developing a new hinge binder, thereby providing confidence in further developing the dihydroisobenzofuran series to further optimise its selectivity and DMPK characteristics. The data in Figure 6 was analysed using an analysis of variance model with the log eosinophil numbers as the response with treatment including the controls fitted as a categorical factor. The plotted intervals represent the 95% confidence interval of the mean response. 
N-(5-(3-hydroxy-3-methylbut-1-yn-1-yl)-2-methoxypyridin-3-yl)methanesulfonamide (19)
N-(5-bromo-2-methoxypyridin-3-yl)methanesulfonamide (7.03 g, 25 mmol) and copper(I) iodide (0.381 g, 2.00 mmol) were dissolved in anhydrous 2-methyltetrahydrofuran (80 mL) and nitrogen was bubbled into the mixture during 10 min at room temperature. Then, 2-methylbut-3-yn-2-ol (3.63 mL, 37.5 mmol), bis(triphenylphosphine)palladium(II) chloride (1.05 g, 1.50 mmol) and triethylamine (13.9 mL, 100 mmol) were added and the mixture stirred and heated. After 28 h at 85 ºC, the reaction exhibited approximately 60% conversion and 2-methylbut-3-yn-2-ol (1.2mL) and bis(triphenylphosphine)palladium(II) chloride (400 mg) added and stirred at 85 ºC for a further 17 h.
Ammonium chloride (120 mL) and 2-methyltetrahydrofuran (80 mL) were added and the mixture filtered through celite. The layers were separated and the aqueous extracted with further 2-methyltetrahydrofuran (2 x 80 mL). The combined organics were washed with brine, dried over sodium sulfate and reduced in vacuo. The resulting residue was purified by column chromatography eluting with 0-100% ethyl acetate in cyclohexane. The approppriate fractions were combined and reduced in vacuo to provide 19 (7.39 g, 104%, contained residual ethyl acetate). 
LCMS (Method

N-{2-(Methyloxy)-5-[7-(trimethylsilyl)-1,3-dihydro-2-benzofuran-5-yl]-3-
pyridinyl}methanesulfonamide (14)
Proceedure A. To a nitrogen degassed solution of chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (38 mg, 0.1 mmol) and N- [5- ethynyl-2-(methyloxy)-3-pyridinyl]methanesulfonamide (226 mg, 1.0 mmol) in CPME (7.5 mL) was added a solution of 13 (200 mg, 1.20 mmol) in CPME (7.5 mL) sequentially, dropwise at room temperature. The mixture was then stirred at room temperature for 24 h. The mixture was concentrated under reduced pressure to afford a crude gum. The gum was loaded in minimal CH2Cl2 onto a silica pre-packed column (10 g) and eluted with 0-100% EtOAc in cyclohexane over 60 min.
The combined relevant fractions were concentrated under reduced pressure to give 14 (250 mg, 64%)
as a white solid.
Proceedure B. To chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (344 mg, 902 µmol) was added a solution of 13 (4.1 g, 18 mmol) in CPME (65 mL) and the mixture was degassed with three alternative applications of vacuum and nitrogen. To the mixture was added a solution of trimethyl[3-(2-propyn-1-yloxy)-1-propyn-1-yl]silane (1.5 g, 9.0 mmol) in CPME (40 mL)
sequentially, dropwise at room temperature. The reaction mixture was then stirred at room temperature for 2 h. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with brine (3 x 50 mL). The aqueous extracts were back extracted with ethyl acetate (50 mL). The combined organic extracts were dried under reduced pressure to afford a crude gum. The gum was loaded in minimal CH2Cl2 onto a silica pre-packed column (340 g) and eluted with 0-10% EtOAc in 
N-[5-(7-Iodo-1,3-dihydro-2-benzofuran-5-yl)-2-(methyloxy)-3-pyridinyl]methanesulfonamide (15)
Iodine monochloride in CH2Cl2 (1 M, 4.33 mL, 4.33 mmol) was added dropwise to a solution of 14 (850 mg, 2.17 mmol) in CH2Cl2 (20 mL) under nitrogen at -10 ºC. The reaction mixture was allowed to warm to 0 ºC and stirred for 5 minutes, during which a white solid precipitated from solution.
Saturated sodium thiosulfate solution (50 mL) was added and the resulting mixture stirred at room temperature for 20 min. The reaction mixture was filtered under reduced pressure and washed with CH2Cl2 (5 mL). The filtrate was poured onto CH2Cl2 (50 mL) and water (30 mL) and the separated aqueous phase was extracted with CH2Cl2 (2 x 50 mL). The combined organic fractions were passed through a hydrophobic frit then concentrated under vacuum to afford a yellow solid. The yellow solid and white solid were combined and triturated in methanol (5 mL). and purified via mass directed auto-preparative (MDAP) chromatography using a Sunfire C18 column and an ammonium bicarbonate-modified MeCN/water gradient. The relevant combined fractions were concentrated under reduced pressure to give a white solid. Water (10 mL) and diethyl ether (10 mL) was added and the mixture filtered and the filter cake was dried under reduced pressure to give 8 
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